<DOC>
	<DOCNO>NCT01001299</DOCNO>
	<brief_summary>This open-label single-arm study evaluate effect RO5185426 [ RG7204 ; PLEXXIKON : PLX4032 ] pharmacokinetics five CYP450 substrate ( caffeine , warfarin + vitamin K , omeprazole , dextromethorphan , midazolam ) administer drug cocktail patient metastatic melanoma . The study also evaluate efficacy safety RO5185426 . On day 1 , patient receive drug cocktail . On day 6 19 , patient receive RO5185426 twice daily . On day 20 , patient receive RO5185426 drug cocktail day 21 25 , patient receive RO5185426 . Assessments make regular interval dose period follow-up . Patients may continue study treatment ( RO5185426 ) development progressive disease unacceptable toxicity . Target sample size &lt; 50 .</brief_summary>
	<brief_title>A Pharmacokinetic Study RO5185426 Combination With Drug Cocktail Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adult patient &gt; /= 18 year age Malignant melanoma ( Stage IV , AJCC ) Patients treatmentnaive receive prior systemic treatment metastatic melanoma . Time elapse previous treatment metastatic disease first administration study drug must least 28 day Positive test BRAF mutation Patients must poor metabolizers CYP450 enzymes 2C9 , 2C19 , 2D6 determine genotyping Measurable disease RECIST criterion Negative pregnancy test ; fertile men woman , effective contraception treatment 6 month completion Active CNS lesion CT/MRI within 28 day prior enrollment History know spinal cord compression , carcinomatous meningitis Severe cardiovascular disease within 6 month prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>